Top Page
Haleon PLC
(LSE:HLN)
Haleon PLC (HLN) vs. S&P 500 (SPY)
Haleon PLC Business Overview & Revenue Model
Haleon PLC Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 11.30B | 10.86B | 9.54B | 9.89B | 8.48B | Gross Profit |
| 6.75B | 6.58B | 5.95B | 5.91B | 4.80B | EBIT |
| 2.00B | 1.82B | 1.64B | 1.60B | 897.00M | EBITDA |
| 2.36B | 2.19B | 2.21B | 1.92B | 1.17B | Net Income Common Stockholders |
| 1.05B | 1.06B | 1.39B | 1.15B | 655.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.04B | 684.00M | 414.00M | 334.00M | 340.00M | Total Assets |
| 34.05B | 34.81B | 34.45B | 34.13B | 35.71B | Total Debt |
| 9.46B | 10.44B | 991.00M | 487.00M | 642.00M | Net Debt |
| 8.41B | 9.76B | 577.00M | 153.00M | 302.00M | Total Liabilities |
| 17.33B | 18.36B | 7.97B | 7.91B | 8.30B | Stockholders Equity |
| 16.61B | 16.33B | 26.36B | 26.11B | 27.32B |
| Cash Flow | Free Cash Flow | |||
| 1.76B | 1.74B | 1.06B | 1.09B | 543.00M | Operating Cash Flow |
| 2.10B | 2.06B | 1.36B | 1.41B | 786.00M | Investing Cash Flow |
| -134.00M | -8.78B | -33.00M | 1.03B | 291.00M | Financing Cash Flow |
| -1.57B | 6.91B | -1.24B | -2.44B | -925.00M |
Haleon PLC Technical Analysis
Haleon PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | £14.57B | 11.44 | 11.89% | 3.11% | -0.38% | 14.68% | |
78 Outperform | £119.20B | 24.43 | 30.27% | 3.15% | -0.76% | -12.83% | |
75 Outperform | £36.11B | 25.23 | 8.80% | 1.65% | -0.61% | 39.00% | |
69 Neutral | £58.65B | 18.76 | 22.52% | 4.47% | 2.57% | -30.13% | |
53 Neutral | £344.40M | ― | -2.48% | 4.38% | -16.16% | 80.50% | |
52 Neutral | $5.17B | 3.59 | -42.19% | 2.82% | 15.05% | -0.04% |
Haleon PLC Earnings Call Summary
Haleon PLC Corporate Events
Haleon PLC announced the purchase and cancellation of 830,504 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s registered share capital and the number of shares with voting rights, impacting shareholder notifications under regulatory guidelines.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a robust financial foundation with strong profitability and cash flow, supporting its growth outlook. Positive market momentum and strategic initiatives like share buybacks enhance investor confidence. However, valuation concerns and external challenges such as currency headwinds and market conditions necessitate cautious optimism.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase and cancellation of 828,853 ordinary shares as part of its ongoing share buyback program. This transaction reflects the company’s strategic financial management, potentially enhancing shareholder value and adjusting its capital structure. The update on the company’s share capital and voting rights is crucial for stakeholders to assess their interests in accordance with regulatory requirements.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a solid financial foundation with strong cash flow and profitability, which forms the core of its stock strength. Despite technical and valuation challenges, the company’s strategic initiatives, including share buybacks and growth in emerging markets, bolster investor confidence. External challenges such as currency headwinds and market conditions are notable, but the overall outlook remains positive.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC has announced the publication of listing particulars for its £10 billion Euro Medium Term Note Programme, which is guaranteed by the company. This routine update is significant as it underscores Haleon’s commitment to maintaining transparency and accessibility for its investors, potentially impacting its financial strategy and market perception.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a solid financial foundation with strong cash flow and profitability, which forms the core of its stock strength. Despite technical and valuation challenges, the company’s strategic initiatives, including share buybacks and growth in emerging markets, bolster investor confidence. External challenges such as currency headwinds and market conditions are notable, but the overall outlook remains positive.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase and cancellation of 832,200 ordinary shares as part of its share buyback program. This move is part of a strategic effort to manage its share capital and potentially enhance shareholder value by reducing the number of shares in circulation, thereby increasing the value of remaining shares.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC’s strong financial performance, particularly in cash flow and profitability, underpins its solid stock rating. The technical indicators show positive momentum, albeit with caution due to high RSI and Stochastic levels. Valuation metrics suggest a moderately high price, which could limit potential gains. The company’s strategic initiatives, including share buybacks and market expansion, reinforce confidence, despite external challenges like currency fluctuations.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the repurchase of 85,611 of its ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction reflects the company’s strategic effort to manage its capital structure and enhance shareholder value, with implications for voting rights and shareholder notifications under regulatory guidelines.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC presents a strong financial foundation with robust profitability and efficient cash flow management. The company’s strategic initiatives, such as share buybacks and innovation-driven growth, reinforce investor confidence. Despite some technical and valuation challenges, along with external headwinds like currency fluctuations, the company’s fundamentals support a moderately positive stock score.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the repurchase of 846,782 ordinary shares as part of its share buyback program, initially announced in March 2025. This transaction is intended to optimize the company’s capital structure and enhance shareholder value. Following this purchase, Haleon’s registered share capital consists of 9,026,151,961 ordinary shares, with 9,022,071,756 shares carrying voting rights. This strategic move is expected to strengthen Haleon’s market position and potentially impact stakeholder interests by adjusting the company’s shareholding structure.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC demonstrates strong financial performance with robust profitability and cash flow management. However, technical indicators and moderate valuation metrics present a balanced outlook. The company’s strategic initiatives, including a significant share buyback program, reinforce investor confidence. External challenges like currency headwinds and market conditions warrant caution, but overall, the company’s fundamentals support a moderately positive stock score.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase and cancellation of 846,648 ordinary shares as part of its share buyback program initiated in March 2025. This transaction adjusts the company’s share capital and affects the number of shares with voting rights, which stakeholders can use to assess their interests under regulatory guidelines.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC demonstrates strong financial performance with robust profitability and cash flow management. However, technical indicators and moderate valuation metrics present a balanced outlook. The company’s strategic initiatives, including a significant share buyback program, reinforce investor confidence. External challenges like currency headwinds and market conditions warrant caution, but overall, the company’s fundamentals support a moderately positive stock score.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase of 855,279 ordinary shares for cancellation as part of its share buyback program. This transaction, which was executed at a volume-weighted average price of 379.18 pence per share, is part of a strategic move to optimize the company’s capital structure and potentially enhance shareholder value. Following this transaction, the company’s registered share capital stands at 9,028,701,792 ordinary shares, with 9,024,621,587 shares holding voting rights, which may impact shareholder notifications under regulatory guidelines.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Neutral.
Haleon PLC demonstrates a strong financial foundation with solid profitability and efficient cash flow management. While the stock faces some technical and valuation challenges, its strategic focus on innovation and emerging market growth, along with shareholder-friendly actions like share buybacks, support a positive outlook. However, external challenges like currency headwinds and market conditions warrant caution.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC has announced its agreement to acquire the remaining 12% equity interest in its Chinese joint venture, Tianjin TSKF Pharmaceutical Co., Ltd., making it a wholly owned subsidiary. This acquisition, valued at approximately £0.2 billion, is expected to be funded through existing cash resources and new Renminbi-denominated debt, with the transaction anticipated to close within three months, pending customary approvals.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a strong financial foundation with solid profitability and efficient cash flow management. The company’s strategic initiatives, including a robust share buyback program and positive earnings guidance, reinforce investor confidence. However, challenges such as currency headwinds and moderate valuation metrics suggest a balanced investment outlook.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase of 865,652 ordinary shares as part of its share buyback program, which was initiated on March 28, 2025. This transaction is part of Haleon’s strategy to manage its capital structure and enhance shareholder value, reflecting confidence in the company’s financial health and future prospects.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a strong financial foundation with solid profitability and efficient cash flow management. The company’s strategic initiatives, including a robust share buyback program and positive earnings guidance, reinforce investor confidence. However, challenges such as currency headwinds and moderate valuation metrics suggest a balanced investment outlook.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase of 887,346 ordinary shares for cancellation as part of its share buyback programme, impacting its share capital and voting rights. This move is part of Haleon’s strategy to manage its capital structure and could influence shareholder decisions under regulatory guidelines.
Spark’s Take on GB:HLN Stock
According to Spark, TipRanks’ AI Analyst, GB:HLN is a Outperform.
Haleon PLC demonstrates a strong financial foundation with solid profitability and efficient cash flow management. The company’s strategic initiatives, including a robust share buyback program and positive earnings guidance, reinforce investor confidence. However, challenges such as currency headwinds and moderate valuation metrics suggest a balanced investment outlook.
To see Spark’s full report on GB:HLN stock, click here.
Haleon PLC announced the purchase of 821,144 ordinary shares for cancellation as part of its share buyback program. This transaction is part of Haleon’s strategy to manage its share capital and potentially enhance shareholder value. The company’s registered share capital now stands at 9,034,845,270 ordinary shares, with 9,030,765,065 shares having voting rights. This move reflects Haleon’s ongoing efforts to optimize its financial structure and could have implications for its market positioning and shareholder engagement.
Haleon PLC announced the purchase of 826,862 ordinary shares for cancellation as part of its share buyback programme initiated on 28 March 2025. This transaction impacts the company’s share capital, reducing the number of ordinary shares with voting rights to 9,032,421,345, which stakeholders can use to assess their interests under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase of 828,379 ordinary shares for cancellation as part of its share buyback program. This transaction affects the company’s share capital, reducing the number of ordinary shares with voting rights to 9,033,248,207. The buyback program is part of Haleon’s strategy to manage its capital structure and potentially enhance shareholder value.
Haleon PLC announced that as of March 31, 2025, the total number of shares issued is 9,038,156,791, with 4,080,205 held as treasury shares. The number of ordinary shares with voting rights is 9,034,076,586, which shareholders should use as the denominator for determining notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the purchase and cancellation of 831,399 ordinary shares as part of its share buyback programme. This transaction is part of their strategy to manage their share capital and potentially enhance shareholder value. The buyback reduces the number of shares with voting rights to 9,034,076,586, which may impact shareholder notifications under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC announced the repurchase of 581,885 ordinary shares as part of its share buyback program, initially announced on March 28, 2025. This transaction is part of Haleon’s strategy to manage its share capital and enhance shareholder value, impacting the number of shares with voting rights, which now stands at 9,034,907,985.
Haleon PLC has announced the purchase and cancellation of 581,885 ordinary shares as part of its share buyback programme. This move is expected to impact the company’s share capital and voting rights, with the number of ordinary shares with voting rights now standing at 9,034,907,985. The buyback is part of Haleon’s strategy to manage its capital structure and enhance shareholder value.
Haleon PLC has announced the commencement of a share buyback programme, aiming to purchase up to £330 million worth of ordinary shares in 2025. This initiative follows a previous off-market purchase from Pfizer Inc. and aligns with Haleon’s capital allocation priorities to enhance shareholder returns. The first tranche of this programme, valued at up to £200 million, will begin immediately and conclude by June 2025, with Goldman Sachs International managing the purchases on the London Stock Exchange. This buyback is expected to reduce the company’s share capital and improve earnings per share, reflecting Haleon’s strategic focus on delivering value to its shareholders.
Haleon PLC announced that Pfizer Inc. has sold its entire residual interest in the company, amounting to 661,709,764 ordinary shares. This transaction, which included a secondary offering and an off-market sale, marks Pfizer’s complete exit from its stake in Haleon, potentially impacting the company’s shareholder structure and market dynamics.
Haleon PLC announced the issuance of share awards to its key executives under various performance and bonus plans. These awards, which are part of the company’s remuneration policy, are designed to incentivize and retain top management by aligning their interests with company performance. The move underscores Haleon’s commitment to maintaining strong leadership and could have implications for its market positioning by ensuring continued strategic focus and operational excellence.
Haleon PLC has completed an off-market purchase of 44,155,844 ordinary shares from Pfizer Inc. for approximately £170 million, subsequently canceling these shares. This transaction affects the total voting rights and capital structure, with the number of ordinary shares with voting rights now standing at 9,035,489,870. This adjustment is significant for shareholders and others with notification obligations under the FCA’s Disclosure Guidance and Transparency Rules.
Haleon PLC has released its Annual Report and Form 20-F for the year ending December 31, 2024. The report is available on the company’s website and has been submitted to both the National Storage Mechanism and the US Securities and Exchange Commission. Shareholders can request a hard copy of the report, which includes the company’s complete audited financial statements. The Annual General Meeting is scheduled for May 28, 2025, with further details to be distributed to shareholders.
Haleon PLC announced a change in its major holdings, with Wellington Management Group LLP increasing its voting rights from 5.1% to 5.87%. This adjustment in holdings reflects Wellington’s strategic positioning and potential influence within Haleon, indicating a strengthened relationship that could impact the company’s future governance and strategic decisions.
Haleon PLC has agreed to purchase 44,155,844 ordinary shares from Pfizer Inc. as part of an off-market transaction, marking Pfizer’s complete exit from its stake in Haleon. This move aligns with Haleon’s capital allocation priorities and strengthens its position to capitalize on future opportunities, as the company continues to focus on delivering attractive returns for shareholders.
Haleon PLC has announced an agreement with Pfizer Inc. to purchase approximately £170 million worth of its own ordinary shares from Pfizer, contingent upon the completion of Pfizer’s proposed offering to institutional investors. This off-market purchase is part of Haleon’s £500 million share buyback plan for 2025, and the company intends to cancel the acquired shares, potentially impacting its market positioning and shareholder value.
Haleon PLC announced the vesting of share awards under its Performance Share Plan 2022 and Share Value Plan 2022, which were granted to key managerial personnel. These awards, which include dividends and are contingent on continued employment and performance conditions, were partially sold to cover tax liabilities. The disclosure aligns with UK Market Abuse Regulation requirements, highlighting Haleon’s commitment to transparency and regulatory compliance.
Haleon PLC announced the acquisition of partnership shares and the award of matching shares to key managerial personnel under the company’s Share Reward Plan. This move, disclosed in compliance with the UK Market Abuse Regulation, involves transactions by Adrian Morris, General Counsel, and Tamara Rogers, Chief Marketing Officer. The transactions, conducted on the London Stock Exchange, reflect Haleon’s commitment to aligning managerial interests with company performance, potentially enhancing stakeholder confidence and reinforcing its market position.
Haleon PLC announced a change to its Board following Pfizer Inc.’s reduction of its shareholding in the company below 10%. As a result, Bryan Supran, a Non-Executive Director and representative of Pfizer, stepped down from the Board. This move aligns with the Pfizer Relationship Agreement with Haleon, marking a significant shift in the company’s governance structure. The departure of Supran, who has been part of Haleon’s journey since its joint venture inception in 2019, signifies a new phase for the company as it continues to solidify its position in the consumer health industry.
Haleon PLC announced disclosures in line with the UK Market Abuse Regulation concerning transactions by individuals in managerial positions. Adrian Morris, the General Counsel, and Tamara Rogers, the Chief Marketing Officer, have both acquired shares under the company’s Share Reward Plan. These transactions were conducted at the London Stock Exchange, involving both Partnership and Matching Shares. Such acquisitions showcase the confidence of Haleon’s leadership in the company’s future prospects and align with its strategic goals to empower key stakeholders.